U.S. Markets closed
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • Dow 30

    34,265.37
    -450.03 (-1.30%)
     
  • Nasdaq

    13,768.92
    -385.08 (-2.72%)
     
  • Russell 2000

    1,987.92
    -36.12 (-1.78%)
     
  • Crude Oil

    84.83
    -0.72 (-0.84%)
     
  • Gold

    1,836.10
    -6.50 (-0.35%)
     
  • Silver

    24.34
    -0.37 (-1.50%)
     
  • EUR/USD

    1.1348
    +0.0031 (+0.2724%)
     
  • 10-Yr Bond

    1.7470
    -0.0860 (-4.69%)
     
  • Vix

    28.85
    +3.26 (+12.74%)
     
  • GBP/USD

    1.3555
    -0.0045 (-0.3321%)
     
  • USD/JPY

    113.6500
    -0.4500 (-0.3944%)
     
  • BTC-USD

    35,661.16
    -2,711.12 (-7.07%)
     
  • CMC Crypto 200

    870.86
    +628.18 (+258.85%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • Nikkei 225

    27,522.26
    -250.64 (-0.90%)
     

Pliant Stock Moves Higher On Positive Data From Pulmonary Fibrosis Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • PLRX
  • Pliant Therapeutics Inc (NASDAQ: PLRX) stock is moving higher during the premarket session in reaction to interim results from a Phase 2a positron emission tomography (PET) imaging-based trial of PLN-74809 for idiopathic pulmonary fibrosis (IPF).

  • PLN-74809 is an oral small molecule dual selective inhibitor of αvβ6/αvβ1.

  • Across four dose levels, all patients achieved greater than 50% target engagement after a single dose of PLN-74809.

  • Single-dose administration of PLN-74809 achieved αvβ6 target engagement up to 98% in the lungs of IPF patients.

  • In addition, there was a dose- and plasma concentration-dependent response with the two highest doses approaching target saturation.

  • PLN-74809 reached highly fibrotic regions of the lung and was bound to αvβ6 in IPF patients.

  • No serious adverse events were reported.

  • Price Action: PLRX shares are up 25.7%% at $24.28 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.